WO2000055344A1 - Vecteur adenoviral exprimant un arn antisens d'antigene sv40 t - Google Patents

Vecteur adenoviral exprimant un arn antisens d'antigene sv40 t Download PDF

Info

Publication number
WO2000055344A1
WO2000055344A1 PCT/US2000/007176 US0007176W WO0055344A1 WO 2000055344 A1 WO2000055344 A1 WO 2000055344A1 US 0007176 W US0007176 W US 0007176W WO 0055344 A1 WO0055344 A1 WO 0055344A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
antigen
nucleic acid
antisense
replication
Prior art date
Application number
PCT/US2000/007176
Other languages
English (en)
Inventor
David S. Schrump
Sheng Guo
Ishrat Waheed
Original Assignee
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority to AU38967/00A priority Critical patent/AU3896700A/en
Publication of WO2000055344A1 publication Critical patent/WO2000055344A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • Figure 1 A DNA based PCR using SV40 T/t antigen specific primers spanning an 838 base pair region (5148 - 4574), resulted in amplified products that corresponded to the T antigen specific DNA bands from the control Cos-7 genomic DNA.
  • the adenovirus is rendered replication deficient, depending upon the specific application of the compounds and methods described herein.
  • Methods of rendering an adenovirus replication deficient are well known in the art. For example, mutations such as point mutations, deletions, and insertions, and combinations thereof, can be directed toward a specific adenoviral gene or genes, such as the El gene.
  • a specific example of the generation of a replication deficient adenovirus for use in gene therapy see WO 94/28938 (Adenovirus Vectors for Gene Therapy Sponsorship) which is incorporated herein.
  • nucleic acid encoding antisense SV40 T antigen or a functional fragment can be administered.
  • the nucleic acid of this invention can be placed into a vector and delivered to the cells of a subject either in vivo or ex vivo by standard methods. Delivery vehicles for vectors are well known and numerous.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un adénovirus de recombinaison déficient du point de vue de la réplication qui comprend l'acide nucléique qui code un acide ribonucléique antisens pour l'antigène SV40 T. Cette invention concerne également des adénovirus de recombinaison déficients du point de vue de la réplication qui comprennent l'acide nucléique codant un acide ribonucléique antisens pour la région proche de SV40T ; un procédé de traitement du cancer par administration d'un adénovirus de recombinaison déficient du point de vue de la réplication comprenant un acide nucléique qui code un acide ribonucléique antisens pour l'antigène SV40 T ; des procédés permettant d'induire l'apoptose, d'arrêter la croissance cellulaire, de réduire les niveaux d'expression de proto-oncogènes, de réguler à la hausse les protéines pro-apoptotiques, de maintenir des niveaux normaux de protéine p 53 fonctionnelle et de maintenir des niveaux fonctionnels de Rb, p107 et p130 au moyen de l'administration d'un adénovirus de recombinaison déficient du point de vue de la réplication comprenant un acide nucléique qui code un acide ribonucléique antisens pour l'antigène SV40 T.
PCT/US2000/007176 1999-03-17 2000-03-17 Vecteur adenoviral exprimant un arn antisens d'antigene sv40 t WO2000055344A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU38967/00A AU3896700A (en) 1999-03-17 2000-03-17 Adenoviral vector expressing a sv40 t antigen antisense rna

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12477699P 1999-03-17 1999-03-17
US60/124,776 1999-03-17

Publications (1)

Publication Number Publication Date
WO2000055344A1 true WO2000055344A1 (fr) 2000-09-21

Family

ID=22416738

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007176 WO2000055344A1 (fr) 1999-03-17 2000-03-17 Vecteur adenoviral exprimant un arn antisens d'antigene sv40 t

Country Status (2)

Country Link
AU (1) AU3896700A (fr)
WO (1) WO2000055344A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143427A1 (fr) * 2011-04-19 2012-10-26 Santaris Pharma A/S Composés anti-polyomavirus

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CARBONE MICHELE ET AL: "Simian virus-40 large-T antigen binds p53 in human mesotheliomas.", NATURE MEDICINE, vol. 3, no. 8, 1997, pages 908 - 912, XP002145106, ISSN: 1078-8956 *
DE LUCA ANTONIO ET AL: "The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas.", NATURE MEDICINE, vol. 3, no. 8, 1997, pages 913 - 916, XP002145107, ISSN: 1078-8956 *
GRAESSMANN M ET AL: "INHIBITION OF SV-40 GENE EXPRESSION BY MICROINJECTED SMALL ANTISENSE RNA AND DNA MOLECULES", NUCLEIC ACIDS RESEARCH, vol. 19, no. 1, 1991, pages 53 - 60, XP002145108, ISSN: 0305-1048 *
GUO Z S ET AL: "EVALUATION OF PROMOTER STRENGTH FOR HEPATIC GENE EXPRESSION IN VIVO FOLLOWING ADENOVIRUS-MEDIATED GENE TRANSFER", GENE THERAPY, vol. 3, 1996, pages 802 - 810, XP000857333, ISSN: 0969-7128 *
JENNINGS PA. ET AL.: "Inhibition of SV40 replicon function by engineered antisense RNA transcribed by RNA polymerase III.", EMBO J 1987 OCT;6(10):3043-7, XP002097311 *
LEVRESSE V. ET AL.: "Effect of simian virus large T antigen expression on cell cycle control and apoptosis in rat pleural mesothelial cells exposed to DNA damaging agents.", ONCOGENE 1998 FEB 26;16(8):1041-53, XP000938450 *
STERMAN DH. ET AL.: "Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.", HUM GENE THER 1998 MAY 1;9(7):1083-92, XP000938429 *
TANAKA YOSHIHARU ET AL: "Phenotypic conversion of SV40-immortalized human diploid fibroblasts to senescing cells by introduction of an antisense gene for SV40-T antigen.", CELL STRUCTURE AND FUNCTION, vol. 17, no. 6, December 1992 (1992-12-01), pages 351 - 362, XP000930065, ISSN: 0386-7196 *
WAHEED ISHRAT ET AL: "Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells.", CANCER RESEARCH, vol. 59, no. 24, 15 December 1999 (1999-12-15), pages 6068 - 6073, XP002145109, ISSN: 0008-5472 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143427A1 (fr) * 2011-04-19 2012-10-26 Santaris Pharma A/S Composés anti-polyomavirus

Also Published As

Publication number Publication date
AU3896700A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
US6143290A (en) Tumor regression by adenovirus expression of wild-type p53
EP0921821B1 (fr) Apoptose induite par 2-methoxyestradiol dans les cellules cancereuses
RU2174409C2 (ru) Способы и композиции для диагностики и лечения рака
US6797702B1 (en) Methods and compositions comprising DNA damaging agents and P53
US20040191223A1 (en) Combinatorial methods for inducing cancer cell death
JP2000515504A (ja) 細胞死を誘導するアデノウイルスｅ４蛋白質
JP4771576B2 (ja) Ｇａｓｃ１遺伝子
WO2000055344A1 (fr) Vecteur adenoviral exprimant un arn antisens d'antigene sv40 t
WO1997016547A9 (fr) VECTEURS D'EXPRESSION ADENOVIRAUX ANTISENS DU K-ras ET LEUR APPLICATION EN THERAPIE ANTICANCEREUSE
CA2292378C (fr) Methode permettant d'inhiber la croissance des cellules cancereuses au moyen d'un vecteur exprimant le gene prb2/p130
JP2003529321A (ja) Ｐ−ｈｙｄｅファミリーの単離された核酸、ｐ−ｈｙｄｅタンパク質、及び癌における細胞死の誘導に対する感受性を誘導する方法
US6835812B1 (en) Human p-Hyde proteins
WO1998030101A1 (fr) Approches de therapie genique de mort de cellule cible pour le traitement du cancer: compositions et methodes
WO1998030101A9 (fr) Approches de therapie genique de mort de cellule cible pour le traitement du cancer: compositions et methodes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase